Pozelimab + cemdisiran for hemoglobinuria, paroxysmal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Feb 2023: Trial registered, NCT05744921
  2. 7 Mar 2023: Trial started, NCT05744921

The trials

NCT05744921: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

State
Under way
Phase
Phase 3
People
202 planned
Started
7 Mar 2023
Primary completion
10 Oct 2028
Arms
PNH Transition Patients, C5 Polymorphism Patients
Results
None posted
  1. 27 Feb 2023: Trial registered
  2. 7 Mar 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.